SRC and prostate carcinoma: In the current study, we investigated if Src is involved in the Y216 phosphorylation and GSK-3 activity regulation, and characterized the efficacy of targeting Src-GSK-3 pathway using pharmacological inhibitors for prostate cancer therapy.